Home » Stocks » Axovant Gene Therapies

Axovant Gene Therapies Ltd. (AXGT)

Stock Price: $3.02 USD 0.05 (1.68%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
After-hours: $3.09 +0.07 (2.32%) Aug 7, 5:38 PM

Stock Price Chart

Key Info

Market Cap 121.81M
Revenue (ttm) n/a
Net Income (ttm) -72.63M
Shares Out 39.53M
EPS (ttm) -2.93
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $3.02
Previous Close $2.97
Change ($) 0.05
Change (%) 1.68%
Day's Open 2.98
Day's Range 2.98 - 3.04
Day's Volume 195,949
52-Week Range 1.41 - 8.08

More Stats

Market Cap 121.81M
Enterprise Value 57.45M
Earnings Date (est) Nov 9, 2020
Ex-Dividend Date n/a
Shares Outstanding 39.53M
Float 15.05M
EPS (basic) -2.93
EPS (diluted) -2.93
FCF / Share -2.73
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 253,583
Short Ratio 1.00
Short % of Float 1.37%
Beta 1.57
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 1.95
Revenue n/a
Operating Income -69.17M
Net Income -72.63M
Free Cash Flow -67.73M
Net Cash 64.36M
Net Cash / Share 1.60
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -39.96%
ROE -123.34%
ROIC -3,948.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 6
Overweight 1
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$13.71*
(353.97% upside)
Low
8.00
Current: $3.02
High
24.00
Target: 13.71
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014
Revenue------
Operating Income-69.17-127-213-180-133-21.05
Net Income-72.63-129-222-181-133-21.05
Shares Outstanding24.8116.1013.4212.3911.812.00
Earnings Per Share-2.93-8.02-16.51-14.56-11.28-10.56
Operating Cash Flow-67.47-134-190-112-53.35-0.68
Capital Expenditures-0.26-0.20-4.28-0.11-0.09-0.01
Free Cash Flow-67.73-134-195-112-53.44-0.69
Cash & Equivalents80.751071542132760.00
Total Debt16.3944.1852.6851.44--
Net Cash / Debt64.3662.821021612760.00
Assets93.681231612232821.12
Liabilities32.1266.4989.5097.7015.768.87
Book Value61.5656.2171.29125267-7.75
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Axovant Gene Therapies Ltd.
Country United Kingdom
Employees 38
CEO Pavan Cheruvu

Stock Information

Ticker Symbol AXGT
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: AXGT

Description

Axovant Gene Therapies Ltd., a clinical-stage company, develops gene therapies for neurodegenerative diseases. The company's product pipeline includes AXO-Lenti-PD program, an in vivo lentiviral gene therapy for the treatment of Parkinson's disease, which is in Phase II clinical trials; the AXO-AAV-GM1 program for the treatment of GM1 gangliosidosis is in Phase I/II clinical trials; and the AXO-AAV-GM2 program for the treatment of GM2 gangliosidosis that is in Phase I/II clinical trials. It has a license agreement with Oxford BioMedica (UK) Ltd.; license and collaboration agreement with Benitec Biopharma Limited; exclusive license agreement with The University of Massachusetts Medical School; and collaboration agreement with Invitae Corporation. The company was formerly known as Axovant Sciences Ltd. The company was founded in 2014 and is based in London, the United Kingdom.